Segmed Gains Independent HIPAA De-Identification Validation Across Imaging and Clinical Data

New updates have been reported about Segmed.

Segmed has obtained an independent Expert Determination confirming that its structured clinical data, medical imaging pixels, and radiology text all meet HIPAA’s de-identification standard, strengthening the company’s position as a compliant provider of real-world medical imaging data for research and AI. This validation, issued by statistical privacy expert Brad Malin, PhD, affirms that Segmed’s datasets present no reasonable basis for re-identifying individuals, covering the three most complex data modalities used in contemporary healthcare research. The company’s de-identification framework combines automated algorithms with human review to remove direct identifiers and assess indirect identifiers, designed to minimize privacy risk while preserving data utility for downstream use in biopharma, AI model training, and clinical innovation. For customers and partners, this determination materially reduces regulatory and reputational risk associated with using large-scale health data, and supports compliant commercialization of products built on Segmed’s data.

The Expert Determination complements Segmed’s existing SOC 2 Type 2 and ISO 27001 certifications, signaling sustained investment in security, governance, and internal controls that are regularly audited against industry standards. CEO David Gascoigne emphasized that the independent review reinforces Segmed’s commitment to privacy and responsible data stewardship, and provides assurance to partners seeking scalable, compliant access to real-world imaging and clinical records. As regulators increase scrutiny of data provenance and privacy in AI and life sciences, Segmed’s combination of HIPAA-compliant de-identification and enterprise-grade security positions the company to capture growing demand for high-quality, privacy-safe datasets. With a global network of healthcare partners and a large library of de-identified imaging datasets delivered through its proprietary platform, Segmed is focusing on infrastructure that can meet both scientific requirements and evolving regulatory expectations, potentially enhancing its attractiveness to pharmaceutical, medical device, and technology customers relying on real-world data at scale.